rr 生物标志物分析原则（NSCL-H）.
vv 晚期或转移性疾病的生物标志物指导治疗原则（NSCL-J）
lll In general, 4 cycles of initial systemic therapy (ie, with carboplatin or cisplatin) are administered prior to maintenance therapy. However, if patient is tolerating therapy well, consideration can be given to continue to 6 cycles.
sss For HER2 protein overexpression (IHC3+) treatment options, see NSCL-K 5 of 6.
ttt For oncogenic or likely oncogenic ERBB2 (HER2) mutations, refer to definitions at oncokb.org. Zongertinib and sevabertinib are FDA-approved for the treatment of tumors with tyrosine kinase domain mutations.
uuu There is an absence of prospective data reporting efficacy of zongertinib after sevabertinib or sevabertinib after zongertinib. NCCN-NSCLC-2026V6 NCCN非小细胞肺癌指南导航
